CY1113200T1 - Οφθαλμικες σταγονες - Google Patents

Οφθαλμικες σταγονες

Info

Publication number
CY1113200T1
CY1113200T1 CY20111100235T CY111100235T CY1113200T1 CY 1113200 T1 CY1113200 T1 CY 1113200T1 CY 20111100235 T CY20111100235 T CY 20111100235T CY 111100235 T CY111100235 T CY 111100235T CY 1113200 T1 CY1113200 T1 CY 1113200T1
Authority
CY
Cyprus
Prior art keywords
water
prostaglandin derivatives
addition
eye drops
hydrogenated
Prior art date
Application number
CY20111100235T
Other languages
English (en)
Inventor
Kenji Morishima
Akio Kimura
Hiroyuki Asada
Masayuki Umeda
Mitsuaki Kuwano
Original Assignee
Santen Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18762864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1113200(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Santen Pharmaceutical Co., Ltd filed Critical Santen Pharmaceutical Co., Ltd
Publication of CY1113200T1 publication Critical patent/CY1113200T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

Ένα αντικείμενο της παρούσας εφεύρεσης αποτελεί η σύνθεση παραγώγων προσταγλανδίνης τα οποία δύσκολα διαλύονται σε νερό και είναι πιθανό να απορροφηθούν σε ένα ρητινώδες δοχείο και παράγωγα προσταγλανδίνης σε οφθαλμικά διαλύματα τα οποία ενδέχεται να αποσυντεθούν αν διαλυθούν σε νερό. Η διαλυτότητα των παραγώγων προσταγλανδίνης σε νερό βελτιώνεται και η απορρόφηση τους στο ρητινώδες δοχείο μπορεί να παρεμποδιστεί σε σημαντικό βαθμό αν προστεθεί στα οφθαλμικά διαλύματα μια μη ιονική επιφανειοδραστική ουσία όπως είναι το πολυσορβικό 80 ή υδρογονωμένο καστορέλαιο πολυοξυαιθυλενίου 60. Η αποσύνθεση των παραγώγων προσταγλανδίνης επιβραδύνεται σε μεγάλο βαθμό με την προσθήκη ενός αντιοξειδωτικού όπως είναι το αιθυλενοδιαμινοτετραοξικό νάτριο ή διβουτυλυδροξυτολουόλιο.
CY20111100235T 2000-09-13 2011-02-28 Οφθαλμικες σταγονες CY1113200T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000277554 2000-09-13
EP01965597A EP1321144B1 (en) 2000-09-13 2001-09-13 Eye drops

Publications (1)

Publication Number Publication Date
CY1113200T1 true CY1113200T1 (el) 2014-04-09

Family

ID=18762864

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111100235T CY1113200T1 (el) 2000-09-13 2011-02-28 Οφθαλμικες σταγονες
CY2011007C CY2011007I2 (el) 2000-09-13 2011-07-28 Οφθαλμικες σταγονες

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2011007C CY2011007I2 (el) 2000-09-13 2011-07-28 Οφθαλμικες σταγονες

Country Status (14)

Country Link
US (4) US20040097592A1 (el)
EP (1) EP1321144B1 (el)
KR (1) KR100854056B1 (el)
CN (1) CN1243548C (el)
AT (1) ATE490761T1 (el)
AU (1) AU2001286210A1 (el)
CA (1) CA2422031C (el)
CY (2) CY1113200T1 (el)
DE (1) DE60143615D1 (el)
DK (1) DK1321144T3 (el)
ES (1) ES2357551T3 (el)
NO (1) NO332650B1 (el)
PT (1) PT1321144E (el)
WO (1) WO2002022131A1 (el)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022131A1 (fr) * 2000-09-13 2002-03-21 Santen Pharmaceutical Co., Ltd. Collyre
KR101027454B1 (ko) * 2002-08-23 2011-04-06 산텐 세이야꾸 가부시키가이샤 라타노프로스트를 유효 성분으로 하는 안정한 점안액
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
DE602004024427D1 (de) * 2003-07-31 2010-01-14 Santen Pharmaceutical Co Ltd Prostaglandin enthaltendes produkt
EP1681059B1 (en) * 2003-11-07 2009-09-09 Senju Pharmaceutical Co., Ltd. Pharmaceutical composition containing prostaglandin
CN102526064A (zh) * 2004-12-09 2012-07-04 参天制药株式会社 含有分子内具有氟原子的前列腺素的制品
ATE555792T1 (de) * 2004-12-24 2012-05-15 Santen Pharmaceutical Co Ltd Prostaglandin f2 alpha derivat enthaltende produkte
GB0501192D0 (en) 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
KR101396731B1 (ko) 2005-03-31 2014-05-19 산텐 세이야꾸 가부시키가이샤 프로스타글란딘 Ｆ２ａ 유도체를 유효 성분으로서 함유하는망막신경세포 보호제
WO2006112313A1 (ja) 2005-04-13 2006-10-26 Ube Industries, Ltd. インダゾール誘導体を有効成分として含む網膜神経細胞保護剤
EP1994933B1 (en) 2006-03-13 2017-04-26 R-Tech Ueno, Ltd. Aqueous composition
FR2912207B1 (fr) * 2007-02-01 2012-10-26 Air Liquide Procede et appareil de production de monoxyde de carbone par distillation cryogenique
KR101475965B1 (ko) * 2007-03-29 2014-12-23 산텐 세이야꾸 가부시키가이샤 플루오로메토론을 함유하는 현탁형 점안제
EP1985298A1 (en) * 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
CN102014920B (zh) 2008-04-23 2012-10-03 大塚制药株式会社 滴眼剂制剂及其应用
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
US20110136898A1 (en) * 2008-08-05 2011-06-09 University College Cork, National University Of Ireland, Cork Treatment of retinal degeneration
WO2010100656A2 (en) * 2009-02-20 2010-09-10 Micro Labs Limited Storage stable prostaglandin product
EP2269575A1 (en) 2009-06-30 2011-01-05 Santen Pharmaceutical Co., Ltd Method for improving bioavailability of latanoprost
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
ES2391721T3 (es) * 2010-03-01 2012-11-29 Laboratorios Salvat, S.A. Disoluciones acuosas transparentes de acetónido de fluocinolona para el tratamiento de la infamación de oído
EP2452669A1 (en) 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmic composition
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
WO2013183778A1 (ja) * 2012-06-08 2013-12-12 ライオン株式会社 粘膜用組成物
CN104288092A (zh) * 2013-07-16 2015-01-21 广东东阳光药业有限公司 拉坦前列素滴眼剂
CN104622798B (zh) * 2014-12-05 2017-12-22 广东东阳光药业有限公司 一种含有他氟前列素的滴眼液及其制备方法
WO2018033854A1 (en) 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
JP7165123B2 (ja) 2017-03-27 2022-11-02 興和株式会社 医薬製剤
US20210282965A1 (en) 2018-07-09 2021-09-16 Warszawskie Zaklady Farmaceutyczne Polfa Sa Opthalmic dispensing device
EP3853317A4 (en) * 2018-09-21 2022-06-22 PS Therapy Ltd. ARTIFICIAL TEARS, CONTACT LENSES AND MEDICATION COMPOSITIONS AND METHODS OF USE THEREOF
JP2022512788A (ja) 2018-10-25 2022-02-07 ネクスモス カンパニー リミテッド アプタミンｃを有効成分として含む点眼液組成物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310543A (en) * 1980-10-09 1982-01-12 Hoffmann-La Roche Inc. Prostaglandin compositions
ES2052735T3 (es) * 1987-09-18 1994-07-16 R Tech Ueno Ltd Un metodo para producir un agente hipotensor ocular.
JPH0662417B2 (ja) * 1987-12-25 1994-08-17 参天製薬株式会社 抗アレルギー点眼液
US5565492A (en) * 1988-07-18 1996-10-15 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
AU665287B2 (en) * 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5486540A (en) * 1993-10-28 1996-01-23 Allergan, Inc. Cyclopentane heptanoic or heptenoic acid, 2-arylalkyl or arylalkenyl and derivatives as therapeutic agents
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
EP0930296B2 (en) * 1996-09-17 2005-11-02 Asahi Glass Company Ltd. Fluorinated prostaglandin derivatives and medicines
JP3480549B2 (ja) * 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6235781B1 (en) * 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
AU743607B2 (en) * 1998-07-14 2002-01-31 Alcon Laboratories, Inc. Prostaglandin product
WO2000038663A2 (en) * 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
WO2000043049A1 (en) * 1999-01-19 2000-07-27 Pharmacia & Upjohn Company Gamma-irradiation sterilized polyethylene packaging
WO2002022131A1 (fr) * 2000-09-13 2002-03-21 Santen Pharmaceutical Co., Ltd. Collyre
TW586946B (en) * 2000-12-22 2004-05-11 Novartis Ag Process to improve stability
DE602004024427D1 (de) * 2003-07-31 2010-01-14 Santen Pharmaceutical Co Ltd Prostaglandin enthaltendes produkt
US20050049311A1 (en) * 2003-09-03 2005-03-03 Pharmacia & Upjohn Company Medicinal products comprising prostaglandin compositions and methods of packaging such compositions

Also Published As

Publication number Publication date
KR100854056B1 (ko) 2008-08-26
CN1457256A (zh) 2003-11-19
ES2357551T3 (es) 2011-04-27
DK1321144T3 (da) 2011-03-07
EP1321144A4 (en) 2009-07-29
ATE490761T1 (de) 2010-12-15
WO2002022131A1 (fr) 2002-03-21
CY2011007I1 (el) 2014-04-09
EP1321144A1 (en) 2003-06-25
US20180353518A1 (en) 2018-12-13
CA2422031A1 (en) 2003-03-12
EP1321144B1 (en) 2010-12-08
NO20031138L (no) 2003-05-12
KR20030029981A (ko) 2003-04-16
NO20031138D0 (no) 2003-03-12
US20040097592A1 (en) 2004-05-20
PT1321144E (pt) 2011-03-10
US20160106757A1 (en) 2016-04-21
AU2001286210A1 (en) 2002-03-26
CN1243548C (zh) 2006-03-01
CA2422031C (en) 2011-11-15
US20070248697A1 (en) 2007-10-25
DE60143615D1 (de) 2011-01-20
NO332650B1 (no) 2012-11-26
CY2011007I2 (el) 2015-08-05

Similar Documents

Publication Publication Date Title
CY1113200T1 (el) Οφθαλμικες σταγονες
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
NO20025590D0 (no) Fenylglycin-derivater
SE7906533L (sv) Pyrrolidinderivat
TR199800436A2 (xx) Primidin t�revlerinin kanserin �nlenmesi i�in kullan�lmas�.
TR200201244T2 (tr) Göz kurumasının iyileştirilmesi için Lipoksin A4 ve analogları
DE60104872D1 (de) Stabilisierte ophthalmische wasserstoffperoxidlösung
ES2111083T3 (es) Composiciones que contienen antibioticos de quinolona y poli(sulfonato de estireno).
ECSP044862A (es) Pirenzepine ophthalmic gel
AR007997A1 (es) Un derivado de distamicina sustituida con acriloilo, sus utilizaciones, un procedimiento para producirlo y una composicion farmaceutica que lo comprende.
ATE117677T1 (de) Indolderivate.
AR025951A1 (es) Derivados de 4-hicroxibifenil hidrazidas y métodos para preparar los derivados.
ATE306475T1 (de) Phenethyl-5-bromopyridylthioharnstoff (pbt) derivative mit spermizider wirkung
GT200200198A (es) Formas pseudopolimorficas de carvedilol
ATE318954T1 (de) Formulierungen fluoreszierender optischer aufheller
SE7811455L (sv) 2-imino-imidazolidin-derivat
EA200201232A1 (ru) Производные сульфонамида
DE69933388D1 (de) Pharmazeutische Lösungen VON TRIPHENYLETHYLEN-ANTIÖSTROGENEN
AU2003298850A8 (en) Quaternary ammonium esters for disinfection and preservation
EA200201234A1 (ru) Производные сульфонамида
EA200200486A1 (ru) Пероральный раствор, содержащий галантамин и подсластитель
DK1272655T3 (da) Stabilisering af meget fölsomme nucleinsyrefarver i vandig oplösning
EA200201023A1 (ru) Ингибитор натрий-водородного обмена типа 1(nhe-1)
PA8474401A1 (es) 3-ceto derivados triciclicos de 6-0-metileritromicina
ES2055631T3 (es) Procedimiento para la produccion de esteres alquilicos de acidos n-(hidroxialquilo)-carbamicos.